Literature DB >> 2950444

[New elements in the symptomatology of visceral larva migrans].

J F Magnaval.   

Abstract

A retrospective study of 92 cases of visceral larva migrans (VLM) seen in Toulouse demonstrated the high prevalence of the disease in the Midi-Pyrénées region (southern France). The patient population was homogeneous, of middle age and predominantly female. The principal symptoms were chronic asthenia of one year duration on average, associated with cutaneous signs of allergy (pruritus, rashes) and with pain in the right hypochondrium. High total IgE level with presence of anti-VLM IgE was more frequent than eosinophilia, which was moderate. In one-third of the cases VLM also seemed to be responsible for an increase in serum gamma GT. VLM is a disease that is often unrecognized. The classical descriptions apply, in reality, to its caricatural forms which are exceptional.

Entities:  

Mesh:

Year:  1987        PMID: 2950444

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  4 in total

1.  Pleural effusion and toxocariasis.

Authors:  T Jeanfaivre; B Cimon; N Tolstuchow; L de Gentile; D Chabasse; E Tuchais
Journal:  Thorax       Date:  1996-01       Impact factor: 9.139

2.  Epidemiologic approach to human toxocariasis in western France.

Authors:  B Gueglio; L de Gentile; J M Nguyen; J Achard; D Chabasse; M Marjolet
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

3.  Application of the western blotting procedure for the immunodiagnosis of human toxocariasis.

Authors:  J F Magnaval; R Fabre; P Maurières; J P Charlet; B de Larrard
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

4.  Evaluation of an immunoenzymatic assay detecting specific anti-Toxocara immunoglobulin E for diagnosis and posttreatment follow-up of human toxocariasis.

Authors:  J F Magnaval; R Fabre; P Maurières; J P Charlet; B de Larrard
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.